Aurobindo Pharma buys four biosimilar drugs from TL Biopharmaceutical

Industry Reports
Typography

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally.

The branded market size of these four biosimilars, three of them monoclonal antibodies in oncology is very promising. Regulatory filing for these products is intended in the period 2020-22. 

Aurobindo is preparing to take its lead molecule from this transaction, a Bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in treating multiple-cancers including metastatic colon or rectal cancer, non-squamous and non-small cell lung cancers

This transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape. Building on these first four products licensed from TL, Aurobindo is expanding its diverse portfolio of eight more next wave of biosimilars ensuring a strong and diverse products pipeline. Aurobindo has set up a fully functional R&D center for biologics development and is also establishing a state-of-art manufacturing facility in Hyderabad, Telangana which would be ready by Q2, FY 18

Commenting on the strategic alliance, Mr. N. Govindarajan, Managing Director of Aurobindo Pharma Limited said: "We are impressed with TL's product developement as these are  developed to the highest standards of biosimilarity. This acquisition is in-line with our strategy of investing in complex products and is on important first step towards establishing Aurobindo's global biosimilar's portfolio.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) , headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals,Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Sign up via our free email subscription service to receive notifications when new information is available.
captcha 

Market Movers

Rogers Corporation

NYQ : ROG - 19 Sep, 2:30pm
127.8886
+0.3886 (+0.3048%) After Hours:
Open 128.0000 Mktcap 2.32B
High 128.0000 52wk Hight 128.0000
Low 127.0300 52wk Low 51.9800
Vol 26544 Avg Vol 120339
Eps 5.5500 P/e 30.8388
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 19 Sep, 2:31pm
6.795
+0.085 (+1.267%) After Hours:
Open 6.780 Mktcap 104.51B
High 6.800 52wk Hight 6.990
Low 6.760 52wk Low 4.190
Vol 3.66M Avg Vol 5.46M
Eps 0.490 P/e 12.560
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 19 Sep, 2:32pm
65.92
-0.07 (-0.11%) After Hours:
Open 66.02 Mktcap 179.79B
High 66.16 52wk Hight 66.80
Low 65.68 52wk Low 58.29
Vol 3.10M Avg Vol 8.07M
Eps 3.87 P/e 35.69
Currency: USD

Johnson & Johnson

NYQ : JNJ - 19 Sep, 2:32pm
135.30
-0.08 (-0.06%) After Hours:
Open 135.02 Mktcap 363.15B
High 135.79 52wk Hight 137.08
Low 134.35 52wk Low 109.32
Vol 2.59M Avg Vol 5.39M
Eps 7.18 P/e 22.89
Currency: USD

Pfizer, Inc.

NYQ : PFE - 19 Sep, 2:32pm
35.50
-0.05 (-0.14%) After Hours:
Open 35.66 Mktcap 211.13B
High 35.66 52wk Hight 35.84
Low 35.35 52wk Low 29.83
Vol 7.99M Avg Vol 17.45M
Eps 2.56 P/e 25.97
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 19 Sep, 12:59pm
13.71
+0.06 (+0.48%) After Hours:
Open 13.71 Mktcap
High 13.71 52wk Hight 16.29
Low 13.71 52wk Low 12.79
Vol 277 Avg Vol 4720
Eps P/e
Currency: USD